CD14 and COVID-19: For example, whereas frequencies of CD14++ CD16− classical monocytes have been reported to be significantly reduced in COVID-19 patients when compared to HCs (115), the proportions of intermediate (CD14++16+) and non-classical (CD14+16++) monocytes are significantly increased (115, 116), with analysis also revealing the percentage of intermediate CD14++16+ monocytes to be significantly higher in patients requiring intensive care unit (ICU) treatment when compared to those with milder disease (116).